



Director/PDMR Shareholding

October 11, 2024

RNS Number : 7887H
Renalytix PLC
11 October 2024

Renalytix plc
("Renalytix" or the "Company")

Director/PDMR Dealing

LONDON and NEW YORK, 11 October 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that on 7 October 2024, certain investment vehicles connected with Christopher Mills, Non-Executive Chairman, sold 83,696 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.08 per Ordinary Share.

Following this transaction, on 8 October 2024, certain investment vehicles connected with Christopher Mills, completed the purchase of 500,000 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.09 per Ordinary Share.

Following completion of both transactions, Christopher Mills and the investment vehicles connected with him are interested in 14,609,946 Ordinary Shares representing 7.7% of the issued share capital of the Company as enlarged by the recent equity placing announced on 30 September 2024.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser and Joint Broker)
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering

Tel: 020 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Harwood Capital LLP*				
2	Reason for the notification					
a)	Position/status	Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood				
b)	Initial notification /Amendment	Initial Notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.0025 each GB00BYWL4Y04				
b)	Nature of the transaction	Sale of Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.08</td> <td>83,696</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.08	83,696
Price(s)	Volume(s)					
£0.08	83,696					
d)	Aggregated information - Aggregated volume - Price	83,696 £0.08				

e)	Date of the transaction	7 October 2024
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Harwood Capital LLP*				
2	Reason for the notification					
a)	Position/status	Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood				
b)	Initial notification /Amendment	Initial Notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.0025 each GB00BYWL4Y04				
b)	Nature of the transaction	Subscription for New Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.09</td> <td>500,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.09	500,000
Price(s)	Volume(s)					
£0.09	500,000					
d)	Aggregated information - Aggregated volume - Price	500,000 £0.09				

e)	Date of the transaction	8 October 2024
f)	Place of the transaction	Off market

**Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher's shareholding is made up of ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP.*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAEEEFSLFAA